True Pundit

Business

‘Pharma Bro’ Martin Shkreli Begins Securities Fraud Trial

FOLLOW US!
Follow on FacebookFollow on Twitter

Martin Shkreli, the former CEO of Turing Pharmaceuticals who gained notoriety for raising the cost of the AIDS drug Daraprim from $13.50 to $750 a pill, begins a long-awaited securities fraud trial on June 26 in Brooklyn, N.Y.

Shkreli is being accused of running a Ponzi-like scheme between two of his companies, Retrophin, Inc. and the hedge fund MSMB Capital Management, between 2009 and 2012. Prosecutors allege Shkreli lied to investors at MSMB and lured them into investing in the company while concealing ruinous trading losses. In order to pay back investors at MSMB, prosecutors allege Shkreli stole money from Retrophin. The defense claims he had good intentions.

“Everybody got paid back in this case,” Shkreli’s lawyer stated, adding that, “Whatever else he did wrong, he ultimately made them whole.”

Although the charges are unrelated to the controversy surrounding Daraprim, Shkreli says prosecutors targeted him for both the drug price hike and his flamboyant personality. The FBI arrested him in December 2015, months after the Daraprim backlash. He has since been free on bail.

Shkreli is also known for his eccentric social media presence, trolling several journalists and notoriously getting banned from Twitter for allegedly harassing a Teen Vogue writer. He is also known for throwing money at various causes, from offering $100,000 for information leading the arrest of the Seth Rich killer to buying the only copy of a Wu-Tang Clan album in 2015 for $2 million. He leaked parts of the album following President Trump’s election victory.

Last week, Shkreli spent hours live-streaming himself playing League of Legends, petting his cat, and casually fiddling with Microsoft Excel documents, not showing any apparent concern about the pending trial.

Shkreli’s trial is expected to last four to six weeks.

Content created by The Daily Caller News Foundation is available without charge to any eligible news publisher that can provide a large audience. For licensing opportunities of our original content, please contact [email protected]

FOLLOW US!
Follow on FacebookFollow on Twitter